Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Matthew Goetz, ESMO 2022: MONARCH 3 trial – Interim overall survival results of abemaciclib + NSAI in patients with HR+, HER2- advanced breast cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 14th 2022

The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 study teach us about the efficacy and safety of abemaciclib plus NSAI in patients with HR+, HER2- advanced breast cancer, the clinical impacts of the availability of abemaciclib, and the results of the interim overall survival analysis.

The abstract entitled ‘MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)‘ Abstract LBA5, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What did the MONARCH 3 study teach us about the efficacy and safety of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+, HER2- advanced breast cancer (ABC)? (0:13)
  2. What has been the clinical impact of the availability of abemaciclib? (1:27)
  3. What were the results of the interim overall survival analysis? (2:27)
  4. Why do you think these findings failed to achieve statistical significance? (3:31)
  5. What further study is needed to optimise the clinical use of abemaciclib in ABC? (3:59)

Disclosures: Matthew P. Goetz serves as a paid consultant and receives grants for research funding paid to his institution from Eli Lilly and Company in support of the MONARCH 3 trial; reports personal fees from Genomic Health; consulting fees to his institution from AstraZeneca, Biovica, Pfizer, Novartis, Sermonix, Context Pharm, Eagle Pharmaceuticals; grants to his institution from Pfizer, Sermonix; honoraria to his institution for serving on the advisory board for ARC Therapeutics, Blueprint Medicines, Biotheranostics, and Sanofi Genzyme; personal fees from Research to Practice, Clinical Education Alliance, Medscape, MJH Life Sciences for CME presentations; and personal fees from Total Health Conferencing serving as a panelist, outside the submitted work.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more breast cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup